Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry)

Am J Cardiol

18 August Aug 2021 one month ago
  • Trabattoni D

Optimal dual antiplatelet therapy (DAPT) duration for patients undergoing percutaneous coronary intervention (PCI) for coronary bifurcations is an unmet issue. The BIFURCAT registry was obtained by merging two registries on coronary bifurcations.

Reference

Benefit of Extended Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients Treated with Drug Eluting Stents for Coronary Bifurcation Lesions (from the BIFURCAT Registry). Filippo O, Kang J, Bruno F, Han JK, Saglietto A, Yang HM, Patti G, Park KW, Parma R, Kim HS, Luca L, Gwon HC, Iannaccone M, Chun WJ, Smolka G, Hur SH, Cerrato E, Han SH, Mario CD, Song YB, Escaned J, Choi KH, Helft G, Doh JH, Giachet AT, Hong SJ, Muscoli S, Nam CW, Gallone G, Capodanno D, Trabattoni D, Imori Y, Dusi V, Cortese B, Montefusco A, Conrotto F, Colonnelli I, Sheiban I, Ferrari GM, Koo BK, D'Ascenzo F. Am J Cardiol. 2021 Aug 2:S0002-9149(21)00635-4. doi: 10.1016/j.amjcard.2021.07.005

Go to PubMed